US 12,655,147 B1Granted

Fused ring compound and pharmaceutical containing same

AssigneeKaken Pharmaceutical Co., Ltd.

InventorsYoshitake Sumikawa, Issei Akahoshi, Masaya Kato

Life of this patent

Estimating the term…

Abstract

The present invention provides a novel compound that has STAT6 inhibitory activity and is effective for treatment of inflammatory diseases such as atopic dermatitis and for allergic diseases. A compound pharmaceutically acceptable salt thereof expressed by general formula (I) having STAT6 inhibitory activity.

Claims30

Dependent claims

A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 19/207,932Filed 14 May 2025 · continuation
Priority: JP 2022-15840930 Sep 2022
Granted: 16 Jun 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification42 codes

A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
C07D 413/10
Containing two hetero rings: linked by a carbon chain containing aromatic rings
A61K 31/404
Condensed with carbocyclic rings, e.g. carbazole: indoles, e.g. pindolol
A61K 31/4184
1,3-Diazoles: condensed with carbocyclic rings, e.g. benzimidazoles

Family

PCT/JP2023/036453Parent of this continuation · filed 29 Sep 2023
Application19/116,232Parent of this continuation
US 2026/0092054 A1Published application
US 12,655,147 B1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results